Literature DB >> 21760578

Vaccines: chasing the dream.

Jim Schnabel.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21760578     DOI： 10.1038/475S18a

Source DB:  PubMed          Journal:  Nature        ISSN： 0028-0836            Impact factor:   49.962


× No keyword cloud information.
  6 in total

1.  Soluble amyloid beta-protein dimers isolated from Alzheimer cortex directly induce Tau hyperphosphorylation and neuritic degeneration.

Authors:  Ming Jin; Nina Shepardson; Ting Yang; Gang Chen; Dominic Walsh; Dennis J Selkoe
Journal:  Proc Natl Acad Sci U S A       Date:  2011-03-18       Impact factor: 11.205

2.  11C-PiB PET assessment of change in fibrillar amyloid-beta load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study.

Authors:  Juha O Rinne; David J Brooks; Martin N Rossor; Nick C Fox; Roger Bullock; William E Klunk; Chester A Mathis; Kaj Blennow; Jerome Barakos; Aren A Okello; Sofia Rodriguez Martinez de Liano; Enchi Liu; Martin Koller; Keith M Gregg; Dale Schenk; Ronald Black; Michael Grundman
Journal:  Lancet Neurol       Date:  2010-02-26       Impact factor: 44.182

Review 3.  Clinical applications of intravenous immunoglobulins in neurology.

Authors:  R A C Hughes; M C Dalakas; D R Cornblath; N Latov; M E Weksler; N Relkin
Journal:  Clin Exp Immunol       Date:  2009-12       Impact factor: 4.330

4.  A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease.

Authors:  S Salloway; R Sperling; S Gilman; N C Fox; K Blennow; M Raskind; M Sabbagh; L S Honig; R Doody; C H van Dyck; R Mulnard; J Barakos; K M Gregg; E Liu; I Lieberburg; D Schenk; R Black; M Grundman
Journal:  Neurology       Date:  2009-11-18       Impact factor: 9.910

5.  Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial.

Authors:  S Gilman; M Koller; R S Black; L Jenkins; S G Griffith; N C Fox; L Eisner; L Kirby; M Boada Rovira; F Forette; J-M Orgogozo
Journal:  Neurology       Date:  2005-05-10       Impact factor: 9.910

6.  Immunomodulation targeting abnormal protein conformation reduces pathology in a mouse model of Alzheimer's disease.

Authors:  Fernando Goñi; Frances Prelli; Yong Ji; Henrieta Scholtzova; Jing Yang; Yanjie Sun; Feng-Xia Liang; Regina Kascsak; Richard Kascsak; Pankaj Mehta; Thomas Wisniewski
Journal:  PLoS One       Date:  2010-10-13       Impact factor: 3.240
  6 in total
  7 in total

1.  Tolfenamic acid downregulates BACE1 and protects against lead-induced upregulation of Alzheimer's disease related biomarkers.

Authors:  Lina Adwan; Gehad M Subaiea; Nasser H Zawia
Journal:  Neuropharmacology       Date:  2014-01-21       Impact factor: 5.250

2.  1α,25-dihydroxyvitamin D3 and resolvin D1 retune the balance between amyloid-β phagocytosis and inflammation in Alzheimer's disease patients.

Authors:  Mathew T Mizwicki; Guanghao Liu; Milan Fiala; Larry Magpantay; James Sayre; Avi Siani; Michelle Mahanian; Rachel Weitzman; Eric Y Hayden; Mark J Rosenthal; Ilka Nemere; John Ringman; David B Teplow
Journal:  J Alzheimers Dis       Date:  2013       Impact factor: 4.472

3.  Effects of human intravenous immunoglobulin on amyloid pathology and neuroinflammation in a mouse model of Alzheimer's disease.

Authors:  Lakshman Puli; Yuriy Pomeshchik; Katja Olas; Tarja Malm; Jari Koistinaho; Heikki Tanila
Journal:  J Neuroinflammation       Date:  2012-05-29       Impact factor: 8.322

4.  Immunomodulation targeting of both Aβ and tau pathological conformers ameliorates Alzheimer's disease pathology in TgSwDI and 3xTg mouse models.

Authors:  Fernando Goñi; Krystal Herline; Daniel Peyser; Kinlung Wong; Yong Ji; Yanjie Sun; Pankaj Mehta; Thomas Wisniewski
Journal:  J Neuroinflammation       Date:  2013-12-13       Impact factor: 8.322

5.  Oriented immobilization of His-tagged protein on a redox active thiol derivative of DPTA-Cu(II) layer deposited on a gold electrode--the base of electrochemical biosensors.

Authors:  Edyta Mikuła; Magdalena Sulima; Ilona Marszałek; Aleksandra Wysłouch-Cieszyńska; Peter Verwilst; Wim Dehaen; Jerzy Radecki; Hanna Radecka
Journal:  Sensors (Basel)       Date:  2013-09-03       Impact factor: 3.576

Review 6.  Treating Alzheimer's disease with monoclonal antibodies: current status and outlook for the future.

Authors:  Niels D Prins; Philip Scheltens
Journal:  Alzheimers Res Ther       Date:  2013-11-11       Impact factor: 6.982

Review 7.  Resolution of Inflammation in Neurodegenerative Diseases: The Role of Resolvins.

Authors:  Sajad Chamani; Vanessa Bianconi; Aida Tasbandi; Matteo Pirro; George E Barreto; Tannaz Jamialahmadi; Amirhossein Sahebkar
Journal:  Mediators Inflamm       Date:  2020-03-25       Impact factor: 4.711
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.